Published in F1000Res on December 21, 2016
Chemopreventive Strategies for Inflammation-Related Carcinogenesis: Current Status and Future Direction. Int J Mol Sci (2017) 0.75
Application of the Onodera prognostic nutrition index and neutrophil-to-lymphocyte ratio in risk evaluation of postoperative complications in Crohn's disease. Sci Rep (2017) 0.75
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 33.12
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature (2001) 28.24
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet (2006) 15.14
Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A (2008) 14.18
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Mucosal flora in inflammatory bowel disease. Gastroenterology (2002) 8.42
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol (2009) 6.10
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med (2012) 4.41
NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut (2004) 4.39
Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med (2013) 3.98
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut (2004) 3.80
Role of the microbiota in immunity and inflammation. Cell (2014) 3.43
Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet (1993) 3.42
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol (2012) 2.88
Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nat Rev Genet (2005) 2.82
Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet (2015) 2.74
The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease. Clin Gastroenterol Hepatol (2014) 2.69
NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun (2004) 2.47
Human α-defensin 6 promotes mucosal innate immunity through self-assembled peptide nanonets. Science (2012) 2.44
Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial. JAMA (2015) 2.43
Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut (2013) 2.32
Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis (2003) 2.06
Crohn's disease: a defensin deficiency syndrome? Eur J Gastroenterol Hepatol (2003) 1.72
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology (2014) 1.57
First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses. Am J Gastroenterol (2014) 1.53
A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology (1982) 1.46
Adherent-invasive Escherichia coli: a putative new E. coli pathotype associated with Crohn's disease. Int J Med Microbiol (2002) 1.45
Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther (2006) 1.33
Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci U S A (2010) 1.29
Paneth's disease. J Crohns Colitis (2010) 1.29
Antimicrobial peptides and gut microbiota in homeostasis and pathology. EMBO Mol Med (2013) 1.17
Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut (2007) 1.11
From intestinal stem cells to inflammatory bowel diseases. World J Gastroenterol (2011) 1.03
Abnormal activation of autophagy-induced crinophagy in Paneth cells from patients with Crohn's disease. Gastroenterology (2012) 1.01
The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Gut Microbes (2010) 1.00
Crohn's disease-derived monocytes fail to induce Paneth cell defensins. Proc Natl Acad Sci U S A (2015) 0.92
The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov model. Clin Gastroenterol Hepatol (2014) 0.88
The Intestinal Microbiota in Inflammatory Bowel Disease. ILAR J (2015) 0.83
IL23R (Interleukin 23 Receptor) Variants Protective against Inflammatory Bowel Diseases (IBD) Display Loss of Function due to Impaired Protein Stability and Intracellular Trafficking. J Biol Chem (2016) 0.81
The association between the gut microbiota and the inflammatory bowel disease activity: a systematic review and meta-analysis. Scand J Gastroenterol (2016) 0.79
Fecal Microbiota Transplantation as a Novel Therapy for Ulcerative Colitis: A Systematic Review and Meta-Analysis. Medicine (Baltimore) (2016) 0.79
Uncoupling of mucosal gene regulation, mRNA splicing and adherent microbiota signatures in inflammatory bowel disease. Gut (2016) 0.79
Meta-analysis of ciprofloxacin in treatment of Crohn's disease. Biomed Rep (2014) 0.77
Autoimmunity in Crohn's Disease-A Putative Stratification Factor of the Clinical Phenotype. Adv Clin Chem (2016) 0.76
Cannabinoid Receptor-2 Ameliorates Inflammation in Murine Model of Crohn's Disease. J Crohns Colitis (2017) 0.75